Rare Disease Day 2026
Rare Disease Day
28 February 2026
More HOPE than you can imagine
As Rare Disease Day approaches on 28 February, we pause to recognise the millions of people worldwide living with a rare condition. While any single rare disease affects a small number of people, collectively they are anything but rare. Over 300 million people globally live with one of the 6,000 identified rare diseases.
There are around 5,000 to 10,000 people with primary sclerosing cholangitis (PSC), in the UK, depending on how you count us.
The ‘diagnostic odyssey’ in rare diseases often leaves patients without answers for too long. For those with PSC, this journey is beset by delays and a lack of approved therapies.
The pace of progress is currently hampered by research barriers: the difficulty of recruiting from a small, rare patient population, the lack of a single diagnostic blood test, and the absence of 'surrogate biomarkers', reliable ways to measure if a drug is working without waiting decades for results. Furthermore, the disconnect between routine test results and how patients actually feel means that the true burden of symptoms like fatigue and itch is often overlooked in clinical trials.
To mark Rare Disease Day, PSC Support sat down with Steve Rossi, Chief Scientific Officer for PSC Partners Seeking a Cure, and Claudia Filozof, Vice President of Fortrea Development Ltd for a fireside chat. Our conversation centred on the power of collaboration in breaking these barriers and accelerating research to develop treatments.
How does patient advocacy influence PSC research?
Patient advocacy ensures the patient voice is not just heard, but is driving the research agenda. At PSC Support, we move beyond being trial subjects to becoming active partners in drug development.
We influence research in many ways, including though:
- Early Engagement: We advocate for pharmaceutical companies to engage with patient groups at the very beginning of clinical trial design, rather than after the protocol is signed.
- Reducing Patient Burden: We provide feedback on trial feasibility to help remove hurdles like excessive biopsies or rigid visit windows that can make participation nearly impossible for people with full-time jobs and families.
- Setting Relevant Endpoints: Through our Patient Panels, we help researchers identify the endpoints that actually matter to us, such as improvements in debilitating symptoms like itch and fatigue.
- Promoting Trials: We maintain interactive trial maps and information to ensure that the 75% of patients who are never even approached about a trial finally have access to these opportunities.
Why is equity of care essential for the rare community?
Access to specialist expertise remains a challenge, as PSC is a complex, immune-mediated disease that often co-exists with inflammatory bowel disease (IBD). Everyone deserves a clear care plan, regardless of where they live. We are working with clinicians to develop a 'PSC Care Bundle' (a standardised checklist) and develop a PSC care pathway ‘blueprint’ to ensure consistent management, monitoring for complications and cancer risk.
What are the latest treatments in development for PSC?
Despite the challenges, we are at a turning point. For decades, a treatment was a distant hope and a cure, out of the question. Today, however, we are entering a new generation of therapies for PSC.
There are now promising studies expected for drugs like nebokitug and elafibranor, and we’ve seen the early positive phase 3 results for others like NCA.
The fact that pharmaceutical companies are investing heavily in PSC research is a testament to the power of our patient advocacy (and very smart scientists and clinicians).
The Power of Collaboration
As Steve Rossi noted during our chat, the most important thing is the power of collaboration. When organisations like PSC Support and PSC Partners come together, we turn a rare, isolated voice into a global movement for change.
This Rare Disease Day, we look forward not with despair, but with the genuine hope that the treatments we needed ‘yesterday’ are finally on the horizon.
How can you help us reach Mission 2030?
PSC Support is committed to establishing a pathway towards finding a cure or effective treatment for everyone with PSC by 2030. Mission 2030 is powered by you, our community.
Every action, from joining a clinical trial, completing one of our surveys, to fundraising for vital research, brings us closer to a breakthrough.
Turning Ambition into Action in 2026:
Our Fortnight in Focus
At PSC Support, we want a world without PSC. We work tirelessly behind the scenes to drive research and improve lives. Here is a snapshot of what we've been up to:
Building Partnerships: We contributed a comprehensive chapter to a new medical textbook for nurses and allied health professionals, ensuring that the patient perspective is integrated into clinical education.
Building Partnerships: We participated in a planning meeting for the update of national clinical guidelines for PSC.
Building Partnerships: We prepared strategic questions for an upcoming international forum titled “Putting Patients First: From Research to Treatment.”
Organisational Excellence: We updated our web details to make it less likely information from us sent by email ends up in your spam folders.
Progressing Research: We are collaborating with European partners to develop a simplified research registry for pregnancy outcomes, building the evidence base needed to improve medical guidance for women with PSC.
Progressing Research: We completed a formal submission to the Scottish Medicines Consortium to advocate for the value of a potential new treatment for PSC patients.
Progressing Research: We reviewed the participant information for a new academic clinical trial to ensure it is clear and accessible for patients.